These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 18096763

  • 1. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.
    Schütz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M.
    Blood; 2008 Apr 01; 111(7):3546-52. PubMed ID: 18096763
    [Abstract] [Full Text] [Related]

  • 2. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation.
    Shen C, He Y, Cheng K, Zhang D, Miao S, Zhang A, Meng F, Miao F, Zhang J.
    Immunol Lett; 2011 Aug 30; 138(2):144-55. PubMed ID: 21513739
    [Abstract] [Full Text] [Related]

  • 3. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
    Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Schölmerich J, Fleck M.
    J Immunol; 2003 Jun 01; 170(11):5406-13. PubMed ID: 12759415
    [Abstract] [Full Text] [Related]

  • 4. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R, Egle A, Villunger A.
    Leuk Lymphoma; 1998 Nov 01; 31(5-6):477-90. PubMed ID: 9922038
    [Abstract] [Full Text] [Related]

  • 5. Targeting antigen-specific T cells by genetically engineered antigen presenting cells. A strategy for specific immunotherapy of autoimmune disease.
    Wu JM, Wu B, Guarnieri F, August JT, Drachman DB.
    J Neuroimmunol; 2000 Jul 01; 106(1-2):145-53. PubMed ID: 10814792
    [Abstract] [Full Text] [Related]

  • 6. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells.
    Zhang HG, Su X, Liu D, Liu W, Yang P, Wang Z, Edwards CK, Bluethmann H, Mountz JD, Zhou T.
    J Immunol; 1999 Feb 01; 162(3):1423-30. PubMed ID: 9973398
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.
    Schütz C, Fleck M, Schneck JP, Oelke M.
    J Vis Exp; 2014 Aug 11; (90):e51859. PubMed ID: 25145915
    [Abstract] [Full Text] [Related]

  • 13. Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity.
    Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton RA, Hartig H, Sundberg JP, Servick S, Kaufmann G, Fink PJ, Chervonsky AV.
    Immunity; 2007 May 11; 26(5):629-41. PubMed ID: 17509906
    [Abstract] [Full Text] [Related]

  • 14. A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo.
    Wang W, Fang K, Li MC, Chang D, Shahzad KA, Xu T, Zhang L, Gu N, Shen CL.
    Oncotarget; 2016 Mar 15; 7(11):12176-90. PubMed ID: 26910923
    [Abstract] [Full Text] [Related]

  • 15. The role and mechanisms of double negative regulatory T cells in the suppression of immune responses.
    Chen W, Ford MS, Young KJ, Zhang L.
    Cell Mol Immunol; 2004 Oct 15; 1(5):328-35. PubMed ID: 16285891
    [Abstract] [Full Text] [Related]

  • 16. Cytotoxic T lymphocytes carrying a pattern recognition protein Tag7 can detect evasive, HLA-negative but Hsp70-exposing tumor cells, thereby ensuring FasL/Fas-mediated contact killing.
    Sashchenko LP, Dukhanina EA, Shatalov YV, Yashin DV, Lukyanova TI, Kabanova OD, Romanova EA, Khaidukov SV, Galkin AV, Gnuchev NV, Georgiev GP.
    Blood; 2007 Sep 15; 110(6):1997-2004. PubMed ID: 17551095
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.
    Wang W, Fang K, Wang X, Li M, Wu Y, Chen F, Shahzad KA, Gu N, Shen C.
    Immunol Invest; 2015 Sep 15; 44(4):385-99. PubMed ID: 25942349
    [Abstract] [Full Text] [Related]

  • 19. Specific immunotherapy of experimental myasthenia gravis in vitro: the "guided missile" strategy.
    Wu JM, Wu B, Miagkov A, Adams RN, Drachman DB.
    Cell Immunol; 2001 Mar 15; 208(2):137-47. PubMed ID: 11333146
    [Abstract] [Full Text] [Related]

  • 20. Involvement of Fas-Fas ligand interactions in graft rejection.
    Martinez OM, Krams SM.
    Int Rev Immunol; 1999 Mar 15; 18(5-6):527-46. PubMed ID: 10672500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.